Bodnar P, Klishch I, Bodnar Y, Bodnar T, Bodnar L
1L.Ya. Kovalchuk Department of Surgery No.1, Urology, Minimally Invasive Surgery I. Horbachevsky Ternopil National Medical University, Ukraine.
2Department of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil National Medical University, Ukraine.
Georgian Med News. 2022 Nov(332):121-124.
Patients with malignancy have higher risk of developing venous thromboembolism. The incidence among different groups of cancer patients varies considerably depending on clinical factors, the most important being tumor entity and stage. The study was approved by the local ethics committee on human research, and written informed consent was obtained from all the study participants. After written informed consent was obtained, a precise medical history was taken, with particular attention to questions about the presence of thrombotic risk factors at the onset of VTE. We retrospectively enrolled 50 patients with Venous Thromboembolism (DVT and PTE) having malignancy and 50 healthy controls from January 2020 to December 2020. DVT were diagnosed using peripheral vascular duplex ultrasonography while PTE was confirmed in all cases by computed tomography. Patients having treatment with anticoagulant therapy, recent surgery less than 8 days previously, refusal or inability to give informed consent, and inability for ascending contrast venography or inadequate results of the venographic examination were excluded from the study. Biomarkers have been specifically investigated for their capacity of predicting venous thromboembolism (VTE) during the course of disease. The relationships between inflammation markers e.g., IL-6, IL-8 and CRP as indicators of the inflammatory process and clinical venous thromboembolism need to be investigated. We investigated IL-6, IL-8 and CRP in 50 patients with venous thromboembolism having malignancy and reported that patients having venous thromboembolism have increased levels of IL-6, IL-8 and CRP (p value < 0.05). Our study concluded that in cancer patients, inflammatory biomarkers play significant role in developing venous thromboembolism. This supports the hypothesis that, markers of systemic inflammatory response are involved in development of thromboembolism in patients with malignancy.
恶性肿瘤患者发生静脉血栓栓塞的风险更高。不同癌症患者群体的发病率因临床因素差异很大，其中最重要的是肿瘤类型和分期。本研究经当地人体研究伦理委员会批准，并获得了所有研究参与者的书面知情同意书。在获得书面知情同意书后，详细记录了患者的病史，尤其关注有关静脉血栓栓塞（VTE）发病时血栓形成危险因素的问题。我们回顾性纳入了2020年1月至2020年12月期间50例患有恶性肿瘤的静脉血栓栓塞（深静脉血栓形成和肺栓塞）患者以及50例健康对照者。深静脉血栓形成通过外周血管双功超声检查诊断，而所有病例的肺栓塞均通过计算机断层扫描确诊。接受抗凝治疗、近期（不到8天前）进行过手术、拒绝或无法给予知情同意以及无法进行静脉造影或静脉造影检查结果不理想的患者被排除在研究之外。已专门研究生物标志物在疾病过程中预测静脉血栓栓塞（VTE）的能力。炎症标志物如IL-6、IL-8和CRP作为炎症过程的指标与临床静脉血栓栓塞之间的关系需要进行研究。我们对50例患有恶性肿瘤的静脉血栓栓塞患者的IL-6、IL-8和CRP进行了研究，结果显示静脉血栓栓塞患者的IL-6、IL-8和CRP水平升高（p值<0.05）。我们的研究得出结论，在癌症患者中，炎症生物标志物在静脉血栓栓塞的发生中起重要作用。这支持了以下假设，即全身炎症反应标志物参与了恶性肿瘤患者血栓栓塞的发生。
